Checkpoint Therapeutics Inc
Company Profile
Business description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Contact
95 Sawyer Road
Suite 110
WalthamMA02453
USAT: +1 781 652-4500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
23
Stocks News & Analysis
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
stocks
These 2 ASX stocks look materially overvalued after earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,809.20 | 9.60 | 0.11% |
| CAC 40 | 8,042.19 | 13.29 | 0.17% |
| DAX 40 | 22,148.03 | 110.20 | 0.50% |
| Dow JONES (US) | 44,368.56 | 225.09 | -0.50% |
| FTSE 100 | 8,807.44 | 30.05 | 0.34% |
| HKSE | 22,191.01 | 333.09 | 1.52% |
| NASDAQ | 19,649.95 | 6.10 | 0.03% |
| Nikkei 225 | 39,574.68 | 610.98 | 1.57% |
| NZX 50 Index | 12,905.98 | 7.97 | -0.06% |
| S&P 500 | 6,051.97 | 16.53 | -0.27% |
| S&P/ASX 200 | 8,545.50 | 10.20 | 0.12% |
| SSE Composite Index | 3,342.22 | 4.17 | -0.12% |